Vir Biotechnology, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vir Biotechnology, Inc.
Having been under GSK's umbrella since 1985, SR One is striking out on its own, having closed the largest first-time VC fund this year.
GlaxoSmithKline's executive team outlined the progress the company is making against COVID-19, lupus nephritis, ovarian cancer and multiple myeloma.
GlaxoSmithKline’s third quarter results included a 9% decline in sales in its vaccine business, but this was offset by tight cost controls and restructuring benefits; the company expects to continue investing in its pipeline and new product launches.
US government’s $450m manufacturing commitment for Regeneron’s antibody cocktail and Gilead’s price for remdesivir drive lower expectations on pricing for the antibody treatments, especially since it seems likely there could be several competing products.
- Large Molecule
- Other Names / Subsidiaries
- Humabs BioMed SA